Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1971 1
1972 17
1973 19
1974 27
1975 19
1976 17
1977 20
1978 21
1979 14
1980 13
1981 7
1982 11
1983 10
1984 7
1985 16
1986 20
1987 42
1988 34
1989 51
1990 55
1991 89
1992 111
1993 110
1994 127
1995 189
1996 238
1997 283
1998 478
1999 582
2000 725
2001 736
2002 670
2003 636
2004 681
2005 691
2006 606
2007 694
2008 673
2009 509
2010 472
2011 453
2012 396
2013 404
2014 374
2015 324
2016 283
2017 265
2018 220
2019 144
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

11,981 results
Results by year
Filters applied: . Clear all
Page 1
Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome.
Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, Zeef LAH, Rozenberg F, Bondet V, Duffy D, Llibre A, Baek J, Sambe MN, Henry E, Jolaine V, Barnerias C, Barth M, Belot A, Cances C, Debray FG, Doummar D, Frémond ML, Kitabayashi N, Lepelley A, Levrat V, Melki I, Meyer P, Nougues MC, Renaldo F, Rodero MP, Rodriguez D, Roubertie A, Seabra L, Uggenti C, Abdoul H, Treluyer JM, Desguerre I, Blanche S, Crow YJ. Rice GI, et al. N Engl J Med. 2018 Dec 6;379(23):2275-7. doi: 10.1056/NEJMc1810983. N Engl J Med. 2018. PMID: 30566312 Free article. No abstract available.
Emerging reverse transcriptase inhibitors for HIV-1 infection.
Rai MA, Pannek S, Fichtenbaum CJ. Rai MA, et al. Expert Opin Emerg Drugs. 2018 Jun;23(2):149-157. doi: 10.1080/14728214.2018.1474202. Epub 2018 May 10. Expert Opin Emerg Drugs. 2018. PMID: 29737220 Free PMC article. Review.
L1 drives IFN in senescent cells and promotes age-associated inflammation.
De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, Caligiana A, Brocculi G, Adney EM, Boeke JD, Le O, Beauséjour C, Ambati J, Ambati K, Simon M, Seluanov A, Gorbunova V, Slagboom PE, Helfand SL, Neretti N, Sedivy JM. De Cecco M, et al. Nature. 2019 Feb;566(7742):73-78. doi: 10.1038/s41586-018-0784-9. Epub 2019 Feb 6. Nature. 2019. PMID: 30728521 Free PMC article.
LINE-1-encoded reverse Transcriptase as a target in cancer therapy.
Sciamanna I, Sinibaldi-Vallebona P, Serafino A, Spadafora C. Sciamanna I, et al. Front Biosci (Landmark Ed). 2018 Mar 1;23:1360-1369. doi: 10.2741/4648. Front Biosci (Landmark Ed). 2018. PMID: 29293438 Review.
Future of nonnucleoside reverse transcriptase inhibitors.
Sluis-Cremer N. Sluis-Cremer N. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):637-638. doi: 10.1073/pnas.1720975115. Epub 2018 Jan 11. Proc Natl Acad Sci U S A. 2018. PMID: 29326232 Free PMC article. No abstract available.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Hakim JG, et al. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3. Lancet Infect Dis. 2018. PMID: 29108797 Free PMC article. Clinical Trial.
11,981 results
Jump to page
Feedback